

bs-5491R**[Primary Antibody]****phospho-MAP4K4 (Ser629) Rabbit pAb**

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —

Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) ELISA (1:5000-10000)
Clonality: Polyclonal		Reactivity: (predicted: Human, Mouse, Rat, Rabbit, Chicken, Dog, Horse)
GeneID: 9448	SWISS: Q95819	Predicted MW.: 142 kDa
Target: MAP4K4 (Ser629)		Subcellular Location: Cytoplasm
Immunogen: KLH conjugated Synthesised phosphopeptide derived from human MAP4K4 around the phosphorylation site of Ser629: TT(p-S)RS.		
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase has been shown to specifically activate MAPK8/JNK. The activation of MAPK8 by this kinase is found to be inhibited by the dominant-negative mutants of MAP3K7/TAK1, MAP2K4/MKK4, and MAP2K7/MKK7, which suggests that this kinase may function through the MAP3K7-MAP2K4-MAP2K7 kinase cascade, and mediate the TNF-alpha signaling pathway. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]		

— SELECTED CITATIONS —

- **[IF=3]** Ming Yao. et al. Atracic Acid Increases the Antitumor Effect of BRAF Inhibitor through the Regulation of the HGK/MEK1/ERK Signaling Pathway. MOL PHARMACOL. 2025 May;;100049 WB ;Mouse. 40544613